相关论文: Tracking tumor evolution via the prostate marker P…

Prostatectomized patients are at risk of resurgence, and for this reason, during a follow-up period, they are monitored for Prostate Specific Antigen (PSA) growth, an indicator of tumor progression. The presence of tumors can be evaluated…

Active surveillance (AS) is a suitable management option for newly-diagnosed prostate cancer (PCa), which usually presents low to intermediate clinical risk. Patients enrolled in AS have their tumor closely monitored via longitudinal…

Prostate cancer is one of the most common cancers in men. It is characterized by a slow growth and it can be diagnosed in an early stage by observing the Prostate Specific Antigen (PSA). However, a relapse after the primary therapy could…

We consider a phase-field model of prostate cancer growth with chemotherapy and antiangiogenic therapy effects which is introduced in [2]. It is comprised of phase-field equation to describe tumor growth, which is coupled to a…

Prostate cancer patients who undergo prostatectomy are closely monitored for recurrence and metastasis using routine prostate-specific antigen (PSA) measurements. When PSA levels rise, salvage therapies are recommended to decrease the risk…

Serum prostate-specific antigen (PSA) is widely used for prostate cancer screening. While the genetics of PSA levels has been studied to enhance screening accuracy, the genetic basis of PSA velocity, the rate of PSA change over time,…

While the 10-year survival rate for localized prostate cancer patients is very good (>98%), side effects of treatment may limit quality of life significantly. Erectile dysfunction (ED) is a common burden associated with increasing age as…

Joint modelling of longitudinal and survival data is increasingly used in clinical trials on cancer. In prostate cancer for example, these models permit to account for the link between longitudinal measures of prostate-specific antigen…

We have previously reported that a 'universal' growth law with fixed scaling exponent p, as proposed by West and collaborators for all living organisms, appears to be able to describe also the growth of tumors in vivo. Here, we investigate…

In patients with biochemical recurrence of prostate cancer and negative PSMA PET/CT, radiomics features extracted from recurrence-prone organs can predict clinical progression and progression-free survival. In a cohort of 132 patients,…

Cancer progression involves the sequential accumulation of genetic alterations that cumulatively shape the tumour phenotype. In prostate cancer, tumours can follow divergent evolutionary trajectories that lead to distinct subtypes, but the…

Imaging demonstrates that preclinical and human tumors are heterogeneous, i.e. a single tumor can exhibit multiple regions that behave differently during both normal development and also in response to treatment. The large variations…

Transrectal biopsies under 2D ultrasound (US) control are the current clinical standard for prostate cancer diagnosis. The isoechogenic nature of prostate carcinoma makes it necessary to sample the gland systematically, resulting in a low…

Cytotoxic chemotherapy is a common treatment for advanced prostate cancer. These tumors are also known to rely on angiogenesis, i.e., the growth of local microvasculature via chemical signaling produced by the tumor. Thus, several clinical…

In this work we present a flexible tool for tumor progression, which simulates the evolutionary dynamics of cancer. Tumor progression implements a multi-type branching process where the key parameters are the fitness landscape, the mutation…

The availability of cancer measurements over time enables the personalised assessment of tumour growth and therapeutic response dynamics. However, many tumours are treated after diagnosis without collecting longitudinal data, and cancer…

The development of mathematical models of cancer informed by time-resolved measurements has enabled personalised predictions of tumour growth and treatment response. However, frequent cancer monitoring is rare, and many tumours are treated…

In this paper we propose a systematic approach to construct mathematical models describing populations of cancer-cells at different stages of disease development. The methodology we propose is based on stochastic Concurrent Constraint…

Background: Low-risk prostate cancer patients enrolled in active surveillance programs commonly undergo biopsies for examination of cancer progression. Biopsies are conducted as per a fixed and frequent schedule (e.g., annual biopsies).…

Low risk prostate cancer patients enrolled in active surveillance (AS) programs commonly undergo biopsies on a frequent basis for examination of cancer progression. AS programs employ a fixed schedule of biopsies for all patients. Such…